# Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy

> **NCT05066607** · PHASE2 · UNKNOWN · sponsor: **Intergroupe Francophone du Myelome** · enrollment: 46 (estimated)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** Isatuximab

## Key facts

- **NCT ID:** NCT05066607
- **Lead sponsor:** Intergroupe Francophone du Myelome
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-11
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05066607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05066607, "Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05066607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*